Howard Feldman
MD, FRCP(C), FAAN (Neurology)
Professor Adjunct
Research & Publications
Biography
Coauthors
Selected Publications
- Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer’s disease (BenfoTeam)Feldman H, Luchsinger J, Léger G, Taylor C, Jacobs D, Salmon D, Edland S, Messer K, Revta C, Flowers S, Jones K, Koulman A, Yarasheski K, Verghese P, Venkatesh V, Zetterberg H, Durant J, Lupo J, Gibson G, Group F. Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer’s disease (BenfoTeam). PLOS ONE 2024, 19: e0302998. PMID: 38809849, PMCID: PMC11135745, DOI: 10.1371/journal.pone.0302998.
- Personal value of Alzheimer's disease biomarker testing and result disclosure from the patient and care partner perspectivePatel K, Yang D, Feldman H, Hsiung G, Nygaard H, Best J, Dwosh E, Robillard J, DeMarco M. Personal value of Alzheimer's disease biomarker testing and result disclosure from the patient and care partner perspective. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2024, 10: e12463. PMID: 38596482, PMCID: PMC10999946, DOI: 10.1002/trc2.12463.
- Clinical value of Alzheimer's disease biomarker testingPatel K, Yang D, Best J, Chambers C, Lee P, Henri‐Bhargava A, Funnell C, Foti D, Pettersen J, Feldman H, Nygaard H, Hsiung G, DeMarco M. Clinical value of Alzheimer's disease biomarker testing. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2024, 10: e12464. PMID: 38596484, PMCID: PMC10999950, DOI: 10.1002/trc2.12464.
- Developing the Healthy Actions and Lifestyles to Avoid Dementia or Hispanos y el ALTo a la Demencia programMoukarzel S, Zlatar Z, Hartman S, Lomas D, Feldman H, Banks S, Group H. Developing the Healthy Actions and Lifestyles to Avoid Dementia or Hispanos y el ALTo a la Demencia program. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2024, 10: e12457. PMID: 38440783, PMCID: PMC10909928, DOI: 10.1002/trc2.12457.
- Potentially Modifiable Dementia Risk Factors in Canada: An Analysis of Canadian Longitudinal Study on Aging with a Multi-Country ComparisonSon S, Speechley M, Zou G, Kivipelto M, Mangialasche F, Feldman H, Chertkow H, Belleville S, Nygaard H, Hachinski V, Pieruccini-Faria F, Montero-Odasso M. Potentially Modifiable Dementia Risk Factors in Canada: An Analysis of Canadian Longitudinal Study on Aging with a Multi-Country Comparison. The Journal Of Prevention Of Alzheimer's Disease 2024, 1-10. DOI: 10.14283/jpad.2024.105.
- Number of completed exercise sessions is associated with slower brain atrophy in MCI over 12 months in the EXERT trialDigma L, Aslanyan V, Brewer J, Bevins E, Katula J, Chmelo E, Hodge H, LaCroix A, Shadyab A, Jacobs D, Salmon D, Feldman H, Pa J, Baker L. Number of completed exercise sessions is associated with slower brain atrophy in MCI over 12 months in the EXERT trial. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.079285.
- CSF tau markers are associated with fine memory discrimination in older adults with amnestic MCI in the EXERT trialFenton L, Aslanyan V, Jacobs D, Salmon D, Brewer J, Rissman R, Feldman H, Shadyab A, LaCroix A, Baker L, Pa J. CSF tau markers are associated with fine memory discrimination in older adults with amnestic MCI in the EXERT trial. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.080157.
- Stable Isotope Labelling Kinetics: Models and methods to evaluate APP production rates with Posiphen treatment in the DISCOVER clinical trialElbert D, Galasko D, Farlow M, Aslanyan V, Pa J, Lucey B, Honig L, Moghekar A, Bateman R, Momper J, Rissman R, Balasubramanian A, Maccecchini M, Feldman H, Group A. Stable Isotope Labelling Kinetics: Models and methods to evaluate APP production rates with Posiphen treatment in the DISCOVER clinical trial. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.077287.
- Virtual Design of the Brain Health Support Program and CAN‐THUMBS UPFeldman H, Belleville S, Nygaard H, Montero‐Odasso M, Chertkow H, Group C. Virtual Design of the Brain Health Support Program and CAN‐THUMBS UP. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.075153.
- Brain Health PRO: An Interactive, Online, Educational Program for DementiaBelleville S, Chertkow H, Feldman H, Nygaard H, Montero‐Odasso M, Anderson N, Bherer L, Ferland G, Camicioli R, Chan S, Cuesta M, Dwosh E, Fiocco A, Gilbert B, Itzhak I, Jarrett P, Laurin D, Liu‐Ambrose T, Lupo J, McGibbon C, Middleton L, Murphy K, Phillips N, Pichora‐Fuller M, Revta C, Savundranayagam M, Sexton A, Smith E, Speechley M, Trigui A, Wittich W, Group C. Brain Health PRO: An Interactive, Online, Educational Program for Dementia. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.075156.
- Virtual Cognitive Testing‐ Neuropsychology, MyCogHealth and CognicitiBrewster P, Hofer S, Jacobs D, Feldman H, Belleville S, Montero‐Odasso M, Nygaard H, Chertkow H, Group C. Virtual Cognitive Testing‐ Neuropsychology, MyCogHealth and Cogniciti. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.075157.
- A Phase 2a proof‐of‐concept double‐blind, randomized, placebo‐controlled trial of nicotinamide in early Alzheimer’s diseaseGrill J, Tam S, Thai G, Pierce A, Green K, Gillen D, Teng E, Kremen S, Beigi M, Rissman R, Leger G, Zhang J, Jin S, Messer K, Feldman H. A Phase 2a proof‐of‐concept double‐blind, randomized, placebo‐controlled trial of nicotinamide in early Alzheimer’s disease. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.077979.
- CAN‐THUMBS UP: Recruitment in the Virtual EraNygaard H, Slack P, Feldman H, Chertkow H, Belleville S, Montero‐Odasso M, Anderson N, Bennett D, Borrie M, Chan S, Jarrett P, Lee A, Lupo J, Matthews G, McGibbon C, Revta C, Robillard J, Shadyab A, Shajan S. CAN‐THUMBS UP: Recruitment in the Virtual Era. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.075155.
- Scalable Multi‐Sensor At Home Assessment of Sleep and Activity in Adults At High Risk for DementiaLim A, Centen A, Montazeri N, Gibson E, Dang‐Vu T, Carrier J, Chan S, Belleville S, Nygaard H, Montero‐Odasso M, Feldman H, Chertkow H, Group C. Scalable Multi‐Sensor At Home Assessment of Sleep and Activity in Adults At High Risk for Dementia. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.076469.
- Prognostic value of plasma biomarkers in a clinical trial of mild‐to‐moderate Alzheimer’s DiseaseQiu Y, Messer K, Jacobs D, Salmon D, Kaplita S, Wellington C, Stukas S, Askew B, Brewer J, Brody M, Donahue L, Drake J, Grossman K, Hendrix S, Jicha G, Leger G, Porsteinsson A, Shadyab A, Taylor C, Thomas R, van Dyck C, Zhang J, Coric V, Qureshi I, Feldman H, Group A. Prognostic value of plasma biomarkers in a clinical trial of mild‐to‐moderate Alzheimer’s Disease. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.076047.
- CAN-Thumbs Up: Recruitment in the virtual eraNygaard H, Slack P, Feldman H, Chertkow H, Belleville S, Montero-Odasso M, Anderson N, Bennett D, Borrie M, Chan S, Jarrett P, Lee A, Lupo J, Matthews G, Mcgibbon C, Revta C, Robillard J, Shadyab A, Shajan S. CAN-Thumbs Up: Recruitment in the virtual era. Journal Of The Neurological Sciences 2023, 455: 121435. DOI: 10.1016/j.jns.2023.121435.
- Impact of a national dementia research program - CCNA- in CanadaChertkow H, Phillips N, Rockwood K, Rosa-Neto P, Smith E, Black S, Masellis M, Dixon R, Nygaard H, Feldman H, Bergman H, Gauthier S, Camicioli R, Lim A, Cashman N, Hsiung G. Impact of a national dementia research program - CCNA- in Canada. Journal Of The Neurological Sciences 2023, 455: 121379. DOI: 10.1016/j.jns.2023.121379.
- The CAN-THUMBS UP brain health support program study: Approaching modifiable risk factors in a virtual settingFeldman H, Belleville S, Nygaard H, Montero-Odasso M, Brewster P, Lim A, Chertkow H, Group C. The CAN-THUMBS UP brain health support program study: Approaching modifiable risk factors in a virtual setting. Journal Of The Neurological Sciences 2023, 455: 121389. DOI: 10.1016/j.jns.2023.121389.
- Virtual cognitive testing in the BHSP- neuropsychology, MyCogHealth and CognicitiBrewster P, Hofer S, Lewis N, Jacobs D, Feldman H, Belleville S, Chertkow H, Nygaard H, Montero-Odasso M, Group C. Virtual cognitive testing in the BHSP- neuropsychology, MyCogHealth and Cogniciti. Journal Of The Neurological Sciences 2023, 455: 121375. DOI: 10.1016/j.jns.2023.121375.
- Optimal Weighting of Preclinical Alzheimer’s Cognitive Composite (PACC) Scales to Improve their Performance as Outcome Measures for Alzheimer’s Disease Clinical TrialsWang X, Jacobs D, Salmon D, Feldman H, Edland S. Optimal Weighting of Preclinical Alzheimer’s Cognitive Composite (PACC) Scales to Improve their Performance as Outcome Measures for Alzheimer’s Disease Clinical Trials. International Journal Of Statistics In Medical Research 2023, 12: 90-96. PMID: 38487620, PMCID: PMC10939003, DOI: 10.6000/1929-6029.2023.12.12.
- Impact of a National Dementia Research Program – the CCNA (Canadian Consortium on Neurodegeneration in Aging) (2342)Chertkow H, Belanger N, Bethell J, Black S, Borrie M, Dixon R, Einstein G, Feldman H, Gauthier S, Hogan D, Masellis M, Maxwell C, McGilton K, Montero-Odasso M, Phillips N, Pilon R, Robillard J, Rockwood K, Walker J, Whitehead V. Impact of a National Dementia Research Program – the CCNA (Canadian Consortium on Neurodegeneration in Aging) (2342). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.2342.
- Role of INPP5D, PTK2B, ZCWPW1 and TREM 2 in Predicting Risk of Progression in Cognitively Impaired Subjects to Alzheimer's Disease (P5.166)Hawkins C, Fok A, Feldman H, Sadovnick D, Hsiung G. Role of INPP5D, PTK2B, ZCWPW1 and TREM 2 in Predicting Risk of Progression in Cognitively Impaired Subjects to Alzheimer's Disease (P5.166). Neurology 2016, 86 DOI: 10.1212/wnl.86.16_supplement.p5.166.
- Frontotemporal Dementia (FTD) with Late-Onset Obsessive-Compulsive Symptoms (OCs): An Individual-Patient Data Meta-Analysis (P6.246)Santibanez R, Sepehry A, Feldman H, Hsiung G. Frontotemporal Dementia (FTD) with Late-Onset Obsessive-Compulsive Symptoms (OCs): An Individual-Patient Data Meta-Analysis (P6.246). Neurology 2016, 86 DOI: 10.1212/wnl.86.16_supplement.p6.246.
- The Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS) Protocol: Known Kindreds and Preliminary Data (P5.003)Boeve B, Rosen H, Boxer A, Dickerson B, Feldman H, Ghoshal N, Goldman J, Graff-Radford N, Grossman M, Hsiung G, Huey E, Irwin D, Jack C, Kantarci K, Knopman D, Kornak J, Mackenzie I, Miller B, Petrucelli L, Rademakers R, Shaw L, Toga A, Trojanowski J, Wszolek Z. The Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS) Protocol: Known Kindreds and Preliminary Data (P5.003). Neurology 2015, 84 DOI: 10.1212/wnl.84.14_supplement.p5.003.
- Contribution of Genetic Risk Factors in Progression from Cognitive Impairment to Alzheimer Disease in 2 Large Canadian Cohorts (S34.001)Omoumi A, Fok A, Feldman H, Sadovnick D, Hsiung G. Contribution of Genetic Risk Factors in Progression from Cognitive Impairment to Alzheimer Disease in 2 Large Canadian Cohorts (S34.001). Neurology 2013, 80 DOI: 10.1212/wnl.80.7_supplement.s34.001.
- Predicting missing biomarker data in a longitudinal study of Alzheimer diseaseLo R, Jagust W, Aisen P, Jack C, Toga A, Beckett L, Gamst A, Soares H, C. Green R, Montine T, Thomas R, Donohue M, Walter S, Dale A, Bernstein M, Felmlee J, Fox N, Thompson P, Schuff N, Alexander G, DeCarli C, Bandy D, Chen K, Morris J, Lee V, Korecka M, Crawford K, Neu S, Harvey D, Kornak J, Saykin A, Foroud T, Potkin S, Shen L, Buckholtz N, Kaye J, Dolen S, Quinn J, Schneider L, Pawluczyk S, Spann B, Brewer J, Vanderswag H, Heidebrink J, Lord J, Petersen R, Johnson K, Doody R, Villanueva-Meyer J, Chowdhury M, Stern Y, Honig L, Bell K, Morris J, Mintun M, Schneider S, Marson D, Griffith R, Clark D, Grossman H, Tang C, Marzloff G, Toledo-Morrell L, Shah R, Duara R, Varon D, Roberts P, Albert M, Pedroso J, Toroney J, Rusinek H, de Leon M, De Santi S, Doraiswamy P, Petrella J, Aiello M, Clark C, Pham C, Nunez J, Smith C, Given C, Hardy P, Lopez O, Oakley M, Simpson D, Ismail M, Brand C, Richard J, Mulnard R, Thai G, Mc-Adams-Ortiz C, Diaz-Arrastia R, Martin-Cook K, DeVous M, Levey A, Lah J, Cellar J, Burns J, Anderson H, Laubinger M, Bartzokis G, Silverman D, Lu P, Graff-Radford MBBCH N, Parfitt F, Johnson H, Farlow M, Herring S, Hake A, van Dyck C, MacAvoy M, Benincasa A, Chertkow H, Bergman H, Hosein C, Black S, Graham S, Caldwell C, Hsiung G, Feldman H, Assaly M, Kertesz A, Rogers J, Trost D, Bernick C, Munic D, Wu C, Johnson N, Mesulam M, Sadowsky C, Martinez W, Villena T, Turner S, Johnson K, Behan K, Sperling R, Rentz D, Johnson K, Rosen A, Tinklenberg J, Ashford W, Sabbagh M, Connor D, Jacobson S, Killiany R, Norbash A, Nair A, Obisesan T, Jayam-Trouth A, Wang P, Lerner A, Hudson L, Ogrocki P, DeCarli C, Fletcher E, Carmichael O, Kittur S, Mirje S, Borrie M, Lee T, Bartha D, Johnson S, Asthana S, Carlsson C, Potkin S, Preda A, Nguyen D, Tariot P, Fleisher A, Reeder S, Bates V, Capote H, Rainka M, Hendin B, Scharre D, Kataki M, Zimmerman E, Celmins D, Brown A, Gandy S, Marenberg M, Rovner B, Pearlson G, Anderson K, Saykin A, Santulli R, Englert J, Williamson J, Sink K, Watkins F, Ott B, Wu C, Cohen R, Salloway S, Malloy P, Correia S, Rosen H, Miller B, Mintzer J. Predicting missing biomarker data in a longitudinal study of Alzheimer disease. Neurology 2012, 78: 1376-1382. PMID: 22491869, PMCID: PMC3345787, DOI: 10.1212/wnl.0b013e318253d5b3.